-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, ORD/IrpAz/htOp/ieGUuYaqF5xBb5Y6IYEpgsHmlIbYJ7YHwBMeHOerhJg7qjrGE frtg4Sg10Cod/nP0JZlCOA== 0001104659-06-018838.txt : 20060323 0001104659-06-018838.hdr.sgml : 20060323 20060323131928 ACCESSION NUMBER: 0001104659-06-018838 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20060317 ITEM INFORMATION: Entry into a Material Definitive Agreement FILED AS OF DATE: 20060323 DATE AS OF CHANGE: 20060323 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 06705700 BUSINESS ADDRESS: STREET 1: 130 WAVERLY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139-4242 BUSINESS PHONE: 6165776000 8-K 1 a06-7542_18k.htm CURRENT REPORT OF MATERIAL EVENTS OR CORPORATE CHANGES

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  March 17, 2006

 

VERTEX PHARMACEUTICALS INCORPORATED

(Exact name of registrant as specified in its charter)

 

MASSACHUSETTS

 

000-19319 

 

04-3039129 

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(IRS Employer Identification
No.)

 

130 Waverly Street

Cambridge, Massachusetts  02139

(Address of principal executive offices) (Zip Code)

 

(617) 444-6100

Registrant’s telephone number, including area code:

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 


 

Item 1.01. Entry into a Material Definitive Agreement.

 

On March 17, 2006, Vertex Pharmaceuticals Incorporated (“Vertex”) and Cystic Fibrosis Foundation Therapeutics Incorporated (“CFFT”) entered into a Second Amendment (“Second Amendment”) to the Research, Development and Commercialization Agreement, dated May 24, 2004, between Vertex and CFFT (as amended, the “Agreement”).

 

The Second Amendment provides that CFFT and Vertex will collaborate on the clinical development of VX-770, a drug candidate being investigated for the treatment of cystic fibrosis, and that CFFT will contribute up to $13.3 million toward certain specified VX-770 development costs incurred by Vertex through the fourth quarter of 2007. CFFT may terminate its obligation to provide such funds on a prospective basis effective on December 31, 2006 or June 30, 2007, upon 60 days’ notice to Vertex. Vertex has the right under the Agreement to develop and commercialize VX-770 worldwide and will pay royalties to CFFT on net sales of VX-770, if any.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

VERTEX PHARMACEUTICALS
INCORPORATED

 

(Registrant)

 

 

March 22, 2006

/s/ Kenneth S. Boger

 

 

Kenneth S. Boger

Senior Vice President and General Counsel

 

2

 -----END PRIVACY-ENHANCED MESSAGE-----